Literature DB >> 15485610

Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial.

Maurie Markman.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15485610     DOI： 10.1007/s11912-004-0070-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  6 in total

1.  Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.

Authors:  Brian G M Durie; Joth Jacobson; Bart Barlogie; John Crowley
Journal:  J Clin Oncol       Date:  2004-04-26       Impact factor: 44.544

2.  Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer?

Authors:  Tait D Shanafelt; Charles Loprinzi; Randolph Marks; Paul Novotny; Jeff Sloan
Journal:  J Clin Oncol       Date:  2004-04-26       Impact factor: 44.544

3.  High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.

Authors:  A R Zander; N Kröger; C Schmoor; W Krüger; V Möbus; N Frickhofen; B Metzner; W Schultze; W E Berdel; M Koenigsmann; E Thiel; H Wandt; K Possinger; L Trümper; R Kreienberg; M Carstensen; E H Schmidt; F Jänicke; M Schumacher; W Jonat
Journal:  J Clin Oncol       Date:  2004-04-26       Impact factor: 44.544

4.  Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

Authors:  Ian Chau; Andy R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

5.  Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

Authors:  Eric P Winer; Donald A Berry; Susan Woolf; David Duggan; Alice Kornblith; Lyndsay N Harris; Richard A Michaelson; Jeffrey A Kirshner; Gini F Fleming; Michael C Perry; Mark L Graham; Stewart A Sharp; Roger Keresztes; I Craig Henderson; Clifford Hudis; Hyman Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

6.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272
  6 in total
  1 in total

1.  Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer.

Authors:  Nicola Jane Lawrence; Felicia Roncolato; Andrew Martin; Robert John Simes; Martin R Stockler
Journal:  JNCI Cancer Spectr       Date:  2018-11-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.